Werewolf Therapeutics (NASDAQ:HOWL) Downgraded by Zacks Research to “Hold”

Zacks Research lowered shares of Werewolf Therapeutics (NASDAQ:HOWL) from a strong-buy rating to a hold rating in a report issued on Tuesday,Zacks reports.

HOWL has been the subject of a number of other research reports. Weiss Ratings raised Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Wall Street Zen upgraded Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Werewolf Therapeutics currently has an average rating of “Hold” and an average price target of $4.00.

Werewolf Therapeutics Trading Up 1.9%

Shares of NASDAQ:HOWL opened at $1.09 on Tuesday. The stock’s 50-day moving average price is $0.98 and its 200-day moving average price is $0.69. Werewolf Therapeutics has a 12-month low of $0.27 and a 12-month high of $1.27. The stock has a market capitalization of $52.97 million, a P/E ratio of -1.43 and a beta of 0.55.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. StoneX Group Inc. increased its position in shares of Werewolf Therapeutics by 174.3% during the third quarter. StoneX Group Inc. now owns 54,856 shares of the company’s stock valued at $51,000 after buying an additional 34,856 shares during the period. Covestor Ltd bought a new position in Werewolf Therapeutics in the third quarter worth about $124,000. Vontobel Holding Ltd. bought a new position in Werewolf Therapeutics in the third quarter worth about $55,000. Vilga Financial Planning LLC bought a new position in Werewolf Therapeutics in the third quarter worth about $49,000. Finally, Squarepoint Ops LLC purchased a new stake in Werewolf Therapeutics in the second quarter worth about $37,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues.

Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.